AI
AVXL icon

Atria Investments’s Anavex Life Sciences AVXL Stock Holding History

Atria Investments’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.1K Sell
25,504
-7,725
-23% -$22.9K ﹤0.01% 2102
2026
Q1 		$102K Buy
33,229
+9,889
+42% +$42.8K ﹤0.01% 2007
2025
Q4 		$83.1K Buy
23,340
+2,429
+12% +$14.9K ﹤0.01% 2011
2025
Q3 		$186K Sell
20,911
-1,199
-5% -$12.2K ﹤0.01% 1961
2025
Q2 		$204K Buy
22,110
+3,406
+18% +$29.1K ﹤0.01% 1919
2025
Q1 		$160K Sell
18,704
-3,980
-18% -$37.6K ﹤0.01% 1849
2024
Q4 		$244K Buy
22,684
+9,384
+71% +$72.2K ﹤0.01% 1697
2024
Q3 		$75.5K Buy
+13,300
New +$76.7K ﹤0.01% 1881

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Atria Investments's AVXL Position: Q2 2026 in Review

Atria Investments reduced its Anavex Life Sciences (AVXL) stake by 23% in Q2 2026, selling an estimated $22.9K and leaving 25,504 shares worth $66.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2102.

Atria Investments first reported a position in AVXL in Q3 2024 and has held it in 8 quarters since. The position peaked at $244K in Q4 2024. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Atria Investments held 25,504 shares of Anavex Life Sciences worth $66.1K as of Q2 2026.
  • Atria Investments sold 7,725 Anavex Life Sciences shares in Q2 2026, an estimated $22.9K.
  • Anavex Life Sciences made up ﹤0.01% of Atria Investments's portfolio in Q2 2026, its #2102 holding.
  • Atria Investments first reported a position in Anavex Life Sciences in Q3 2024 and has held it in 8 quarters since.
  • Atria Investments's Anavex Life Sciences position peaked at $244K in Q4 2024.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.